SCHEMBL4453355

SCHEMBL4453355

Cn1cnc2c1c(=O)n(OC(=O)c1ccccc1O)c(=O)n2C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 8/20 0.49
ACHE P22303 2/20 0.49
PIK3CD O00329 1/20 0.49
POLB P06746 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
CNR1 P21554 1/20 0.49
ADORA2A P29274 1/20 0.49
ADORA1 P30542 1/20 0.49
NTSR1 P30989 1/20 0.49
MC3R P41968 1/20 0.49
NOTUM Q6P988 1/20 0.49
SIRT3 Q9NTG7 1/20 0.49
GDA Q9Y2T3 1/20 0.49
NR2E1 Q9Y466 1/20 0.49
TNF P01375 4/20 0.44
TSHR P16473 2/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5430755 0.99 ADORA2B (0.48) ADORA2BACHEPIK3CDPOLBADORA3
SCHEMBL122391 0.99 ADORA2B (0.48) ADORA2BACHEPIK3CDPOLBADORA3
SCHEMBL122001 0.99 ADORA2B (0.48) ADORA2BACHEPIK3CDPOLBADORA3
Caffeine SCHEMBL667174 0.81 ADORA2B (0.62) ADORA2BACHEPIK3CDPOLBADORA3
Caffeine SCHEMBL2468803 0.79 ADORA2B (0.59) ADORA2BACHEPIK3CDPOLBADORA3
SCHEMBL1764613 0.78 ADORA2B (0.61) ADORA2BACHEPIK3CDPOLBADORA3
SCHEMBL3119654 0.77 ADORA2B (0.60) ADORA2BACHEPIK3CDPOLBADORA3
Caffeine SCHEMBL7614321 0.74 ADORA2B (0.53) ADORA2BACHEPIK3CDPOLBADORA3
SCHEMBL684044 0.72 ADORA2B (0.49) ADORA2BACHEPIK3CDPOLBADORA3
Caffeine SCHEMBL10638955 0.71 ADORA2B (0.73) ADORA2BACHEPIK3CDPOLBADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090304821-A1 Pharmaceutical Combination TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed
EP-1992348-A1 PHARMACEUTICAL COMBINATION Takeda Pharmaceutical Company Limited (JP) 2008-11-19 EP disclosed
EP-0969843-B1 ANTITUSSIVE COMPOSITIONS CONTAINING THEOBROMINE KORBONITS DEZSO (HU) 2002-06-12 EP disclosed
US-6348470-B1 ALLEVIATE COUGH WITH THEOBROMINE GAINE, INC. 2002-02-19 US disclosed
EP-0969843-A2 ANTITUSSIVE COMPOSITIONS CONTAINING THEOBROMINE Korbonits, Dezso (HU) 2000-01-12 EP disclosed
WO-1998042322-A2 ANTITUSSIVE COMPOSITIONS KORBONITS DEZSO (HU) 1998-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090304821-A1 Pharmaceutical Combination CALCR, CALCRL, CASR ADORA2B 235/4885ACHE 2987/4885PIK3CD 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.